S&P 500   4,294.12 (-1.00%)
DOW   33,749.22 (-0.76%)
QQQ   355.74 (-1.08%)
AAPL   173.04 (-1.73%)
MSFT   312.85 (-1.48%)
META   298.74 (-0.69%)
GOOGL   127.94 (-2.42%)
AMZN   127.21 (-3.09%)
TSLA   248.02 (+0.42%)
NVDA   424.99 (+0.66%)
NIO   8.45 (+1.20%)
BABA   86.36 (-0.99%)
AMD   97.16 (-0.23%)
T   14.92 (-0.93%)
F   12.50 (-0.64%)
MU   68.45 (-0.19%)
CGC   1.03 (+9.24%)
GE   110.67 (-0.94%)
DIS   80.23 (-0.96%)
AMC   8.26 (+1.47%)
PFE   32.63 (-1.06%)
PYPL   58.84 (-0.03%)
NFLX   383.49 (-0.34%)
S&P 500   4,294.12 (-1.00%)
DOW   33,749.22 (-0.76%)
QQQ   355.74 (-1.08%)
AAPL   173.04 (-1.73%)
MSFT   312.85 (-1.48%)
META   298.74 (-0.69%)
GOOGL   127.94 (-2.42%)
AMZN   127.21 (-3.09%)
TSLA   248.02 (+0.42%)
NVDA   424.99 (+0.66%)
NIO   8.45 (+1.20%)
BABA   86.36 (-0.99%)
AMD   97.16 (-0.23%)
T   14.92 (-0.93%)
F   12.50 (-0.64%)
MU   68.45 (-0.19%)
CGC   1.03 (+9.24%)
GE   110.67 (-0.94%)
DIS   80.23 (-0.96%)
AMC   8.26 (+1.47%)
PFE   32.63 (-1.06%)
PYPL   58.84 (-0.03%)
NFLX   383.49 (-0.34%)
S&P 500   4,294.12 (-1.00%)
DOW   33,749.22 (-0.76%)
QQQ   355.74 (-1.08%)
AAPL   173.04 (-1.73%)
MSFT   312.85 (-1.48%)
META   298.74 (-0.69%)
GOOGL   127.94 (-2.42%)
AMZN   127.21 (-3.09%)
TSLA   248.02 (+0.42%)
NVDA   424.99 (+0.66%)
NIO   8.45 (+1.20%)
BABA   86.36 (-0.99%)
AMD   97.16 (-0.23%)
T   14.92 (-0.93%)
F   12.50 (-0.64%)
MU   68.45 (-0.19%)
CGC   1.03 (+9.24%)
GE   110.67 (-0.94%)
DIS   80.23 (-0.96%)
AMC   8.26 (+1.47%)
PFE   32.63 (-1.06%)
PYPL   58.84 (-0.03%)
NFLX   383.49 (-0.34%)
S&P 500   4,294.12 (-1.00%)
DOW   33,749.22 (-0.76%)
QQQ   355.74 (-1.08%)
AAPL   173.04 (-1.73%)
MSFT   312.85 (-1.48%)
META   298.74 (-0.69%)
GOOGL   127.94 (-2.42%)
AMZN   127.21 (-3.09%)
TSLA   248.02 (+0.42%)
NVDA   424.99 (+0.66%)
NIO   8.45 (+1.20%)
BABA   86.36 (-0.99%)
AMD   97.16 (-0.23%)
T   14.92 (-0.93%)
F   12.50 (-0.64%)
MU   68.45 (-0.19%)
CGC   1.03 (+9.24%)
GE   110.67 (-0.94%)
DIS   80.23 (-0.96%)
AMC   8.26 (+1.47%)
PFE   32.63 (-1.06%)
PYPL   58.84 (-0.03%)
NFLX   383.49 (-0.34%)
OTCMKTS:VDRM

ViaDerma (VDRM) Stock Forecast, Price & News

0.01
0.00 (-2.54%)
(As of 09/25/2023 08:55 PM ET)
Compare
Today's Range
0.01
▼
0.01
50-Day Range
0.01
▼
0.02
52-Week Range
0.00
▼
0.03
Volume
629,400 shs
Average Volume
3.94 million shs
Market Capitalization
N/A
P/E Ratio
0.00
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesShort Interest

VDRM stock logo

About ViaDerma (OTCMKTS:VDRM) Stock

ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.

VDRM Price History

VDRM Stock News Headlines

July 6, 2023 | finance.yahoo.com
ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More
April 18, 2023 | finance.yahoo.com
ViaDerma, Inc. (VDRM) Stock Historical Prices & Data - Yahoo Finance
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
March 16, 2023 | finance.yahoo.com
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
March 8, 2023 | finance.yahoo.com
ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product
March 2, 2023 | finance.yahoo.com
ViaDerma Provides an Update on Current & Future Business Activities
January 12, 2023 | benzinga.com
ViaDerma Retains Digital Marketing Leader INTENT SCIENCES to Accelerate Business Growth Online
September 15, 2022 | finance.yahoo.com
ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
June 22, 2022 | finance.yahoo.com
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products
April 1, 2022 | nz.finance.yahoo.com
Avoteo emerges as the first crowdfunding platform without spending money
April 1, 2022 | yahoo.com
Victoria and David Beckham's UK home 'burgled' while daughter Harper was asleep upstairs
April 1, 2022 | yahoo.com
Our existence isn't new, but now transgender people are visible like never before
March 31, 2022 | finance.yahoo.com
ViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous Year
October 4, 2021 | finance.yahoo.com
ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra
August 24, 2021 | finance.yahoo.com
ViaDerma, Inc. Files Amended Financial Statements
August 21, 2021 | barrons.com
ViaDerma Inc.
See More Headlines
Receive VDRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViaDerma and its competitors with MarketBeat's FREE daily newsletter.

VDRM Company Calendar

Today
9/26/2023
Next Earnings (Estimated)
10/17/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:VDRM
CUSIP
N/A
CIK
N/A
Web
viadermalicensing.com
Phone
(310) 734-6111
Fax
N/A
Employees
75
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
0.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Qing Hua Lin (Age 42)
    Chief Financial Officer and Director
    Comp: $4.46k
  • Mr. Baotang Zhao (Age 45)
    Chief Sales Officer
    Comp: $28.77k
  • Mr. Zhang Xie (Age 44)
    Corp. Sec. and Director
    Comp: $9.18k
  • Dr. Christopher A Otiko
    Founder, Chief Exec. Officer and Pres
  • Dr. Andrew Berman M.D.
    MPH, Medical Director and Member of Advisory Board

Key Competitors

View All Competitors













VDRM Stock - Frequently Asked Questions

How have VDRM shares performed in 2023?

ViaDerma's stock was trading at 0.01 at the start of the year. Since then, VDRM shares have increased by 85.5% and is now trading at 0.01.
View the best growth stocks for 2023 here.

When is ViaDerma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 17th 2023.
View our VDRM earnings forecast.

What is ViaDerma's stock symbol?

ViaDerma trades on the OTCMKTS under the ticker symbol "VDRM."

How do I buy shares of ViaDerma?

Shares of VDRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViaDerma's stock price today?

One share of VDRM stock can currently be purchased for approximately 0.01.

How can I contact ViaDerma?

ViaDerma's mailing address is 4640 Admiralty Way, Suite 500, Marina del Rey, CA 90292, United States. The official website for the company is viadermalicensing.com. The company can be reached via phone at (310) 734-6111.

This page (OTCMKTS:VDRM) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -